Moderna Says Trials Show Vaccine 95% Effective 6 Months After Second Shot

Moderna's COVID-19 vaccine is reported to be more than 90% effective at protecting against COVID-19 and more than 95% effective against severe disease up to six months after the second dose.

The Cambridge, Massachusetts based company cited updated data from its phase three clinical trial, which brings it a step closer to filing its request for full U.S. approval for its vaccine, CNBC reports.

If approved, Moderna will then be able to market its shots directly to consumers and sell them to individuals and private companies nationwide.

The Moderna vaccine is currently authorized for emergency use by the Food and Drug Administration for individuals 18 and older and can have its emergency use authorization revoked at any time.

The Massachusetts company had previously submitted two months of follow-sup safety data for its emergency use authorization and the FDA typically requires a sixth-month follow-up to authorize full approval.

Moderna's new findings included more than 900 cases, including more than 100 severe cases, in its recent preliminary results, adding that it expects to share updated data on efficacy against asymptomatic infection, as well as the persistence of antibodies, at some point in the future.

The new data follows a study published by the New England Journal of Medicine, which revealed antibodies induced by the Moderna vaccine remained present for six months after a second dose was administered, as well as Pfizer announcing its own highly effective results six months after its second dose.

Photo: Getty Images

Sponsored Content

Sponsored Content